Compare Home Depot Inc (HD) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Home Depot Inc vs BIO-TECHNE Corp — how do they compare? Home Depot Inc trades at $331.92 (market cap $332.08B), while BIO-TECHNE Corp trades at $71.54 (market cap $11.16B). The key difference: Home Depot Inc is far larger — about 29.8× BIO-TECHNE Corp's market cap, and Home Depot Inc pays the higher dividend (2.8%). Which is the better fit depends on your goals.
| HD | TECH | |
|---|---|---|
Market Cap | $332.08B | $11.16B |
Sector | Consumer Cyclical | Health |
52-Week High | $423.42 | $72.12 |
52-Week Low | $297.51 | $43.31 |
Enterprise Value | $393.64B | $11.24B |
Dividend Yield | 2.8% | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Home Depot (HD) trades at $330.95, down 2.34% on the day, approaching its 52-week low amid broader market weakness in home improvement stocks. The company reported mixed quarterly earnings with a Q3 2025 miss but subsequent beats, while maintaining solid profitability with 8.41% net margins and strong ROE of 128.38%. Technical indicators show a bearish trend with key support at $321, while analysts maintain a predominantly bullish outlook with a $370.59 consensus price target representing 12% upside potential.
The outlook balances near-term headwinds from weakening big-ticket demand and rising mortgage rates against long-term strengths in Pro segment growth and housing market tailwinds. Investment opportunities include the stock's discount to analyst targets and resilient business model, while risks include margin pressure from investments, competitive threats, and sensitivity to housing market cycles.
Bio-Techne (TECH) trades at $71.64, down 0.67% today, near its 52-week high following Merck KGaA's $73 per share acquisition offer. The stock shows bullish technical signals with strong moving averages, though RSI indicates overbought conditions. Recent earnings have been mixed, with Q4 2025 beating expectations but Q1 2026 missing. The company maintains solid gross margins of 64.96% but faces declining net income margins, down to 6.01% in 2025 from 25.09% in 2023.
The outlook is heavily influenced by the pending acquisition, offering a clear exit near current levels. Risks include shareholder litigation over deal fairness and fundamental profitability pressures. With a high P/E of 103.03, the stock's upside appears capped without the deal, while the $73 bid provides a near-term floor. Investors should weigh acquisition completion probability against operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Home Depot Inc
Home Depot is the world's largest home improvement specialty retailer, operating more than 2,300 warehouse-format stores offering more than 30,000 products in store and 1 million products online in the United States, Canada, and Mexico. Its stores offer numerous building materials, home improvement products, lawn and garden products, and decor products and provide various services, including home improvement installation services and tool and equipment rentals. The acquisition of distributor Interline Brands in 2015 allowed Home Depot to enter the maintenance, repair, and operations business, which has been expanded through the tie-up with HD Supply (2020). The addition of the Company Store brought textile exposure to Home Depot's lineup.
Read more on HD →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
